Patil V, Kumar S, Noronha V, Menon N, et al. Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral Oncol 2022;134:106085.
PMID: 36126602